Diagnostic value of the optic nerve sheath subarachnoid space in patients with intracranial hypotension syndrome

University of Yamanashi (山梨大学)博士(医学)医工博乙第62号　Journal of Neurosurgery 117:372–377, 2012　に掲載。http://dx.doi.org/10.3171/2012.5.JNS1271doctoral thesi

現代日本語における接続助詞で終わる言いさし表現について―「けど」「から」を中心に―

2008-03-31departmental bulletin pape

シュレム・アレイヘム『市場から』のラテン文字転写及び翻訳 2

application/pdf英米言語文化研究. 2001, 49, p.87-108departmental bulletin pape

Improved Constraints on D0-D̅0 Mixing in D0→K+π- Decays from the Belle Detector

journal articl

The Potential of Bemegride as an Activation Agent in Electroencephalography in Dogs

The present study investigated the potential of bemegride as a pharmacological activation agent that elicits epileptiform discharges (EDs) in interictal electroencephalogram (EEG) recordings in dogs. Four laboratory dogs with idiopathic epilepsy and four without epilepsy were included. The dogs were anesthetized using sevoflurane during EEG recordings. Bemegride was administered intravenously and repeatedly until EDs were enhanced or induced, or until the maximum dose (20 mg/kg) had been administered. Bemegride activated EDs in all dogs with epilepsy. These EDs predominantly occurred in each dog’s spontaneous irritative zones, which were identified without the administration of bemegride. EDs occurred after the administration of bemegride in 50% of dogs without epilepsy. The dose required for activation was significantly lower in dogs with epilepsy (median; 7.3 mg/kg) than in those without (median; 19.7 mg/kg) (p = 0.0294). The only suspected adverse effect associated with the administration of bemegride was vomiting in two dogs after awakening from anesthesia. There were no other adverse effects, including seizures. The present results demonstrated the potential of bemegride as a safe and effective pharmacological activation agent of EDs in anesthetized dogs with epilepsy and provided more options for the diagnosis and therapeutic planning of epilepsy, including presurgical evaluations, in dogs

Identification of metabolites with anticancer properties by computational metabolomics-1

Ls after 72 h of incubation in the presence of the tested metabolite at a concentration of 100 μmol/L. Effect of metabolites predicted to be lowered (A), increased (B) or unchanged (C) in Jurkat cells when compared with normal lymphoblasts, on the proliferation of Jurkat cells (2 biological replicates, each with 4 analytical replicates). MQ = menaquinone; HS = α-hydroxystearic acid; DE = dehydroepiandrosterone; SU = 3-sulfino-L-alanine; DM = 5,6-dimethylbenzimidazole; SE = seleno-L-methionine; RB = riboflavin; TN = tryptamine; HA = hydroxyacetone; BR = bilirubin; AT = androsterone; HV = homovanillic acid; VA = vanillylmandelic acid; AA = N-acetyl-L-aspartate; TA = taurocholic acid, CA = citric acid; PA = pantothenic acid; GA = β-D-galactose; FA = folic acid; CH = cholesterol. Error bars represent standard error of mean.<p><b>Copyright information:</b></p><p>Taken from "Identification of metabolites with anticancer properties by computational metabolomics"</p><p>http://www.molecular-cancer.com/content/7/1/57</p><p>Molecular Cancer 2008;7():57-57.</p><p>Published online 17 Jun 2008</p><p>PMCID:PMC2453147.</p><p></p

Identification of metabolites with anticancer properties by computational metabolomics-2

Lls when enzymes that produce X are upregulated and/or enzymes that consume X are downregulated in cancer cells. (B) The intracellular level of a metabolite X is predicted to be decreased in cancer cells when enzymes that produce X are downregulated and/or enzymes that consume X are upregulated in cancer cells. See Material and Methods for a complete description of the rules.<p><b>Copyright information:</b></p><p>Taken from "Identification of metabolites with anticancer properties by computational metabolomics"</p><p>http://www.molecular-cancer.com/content/7/1/57</p><p>Molecular Cancer 2008;7():57-57.</p><p>Published online 17 Jun 2008</p><p>PMCID:PMC2453147.</p><p></p

Identification of metabolites with anticancer properties by computational metabolomics-0

Lls when enzymes that produce X are upregulated and/or enzymes that consume X are downregulated in cancer cells. (B) The intracellular level of a metabolite X is predicted to be decreased in cancer cells when enzymes that produce X are downregulated and/or enzymes that consume X are upregulated in cancer cells. See Material and Methods for a complete description of the rules.<p><b>Copyright information:</b></p><p>Taken from "Identification of metabolites with anticancer properties by computational metabolomics"</p><p>http://www.molecular-cancer.com/content/7/1/57</p><p>Molecular Cancer 2008;7():57-57.</p><p>Published online 17 Jun 2008</p><p>PMCID:PMC2453147.</p><p></p

油圧工学研究会報告

rights: 社団法人日本機械学会 rights: 本文データは学協会の許諾に基づきCiNiiから複製したものである relation: IsVersionOf: http://ci.nii.ac.jp/naid/110002443848/textapplication/pdfjournal articl